↑ 疾患リストへ ← 戻る

 18. 脊髄小脳変性症(多系統萎縮症を除く。) [臨床試験数:14,薬物数:11(DrugBank:5),標的遺伝子数:20,標的パスウェイ数:11] 

Searched query = "Spinocerebellar degeneration"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04107740February 20, 201914 October 2019C-Trelin Orally Disintegrated(OD) Tablet 5mg in Ataxia Due to Spinocerebellar DegenerationMulticenter, Randomized, Double-blind, Placebo-controlled, Phase IV Clinical Trial to Evaluate and Compare the Safety and Efficacy of C-Trelin OD Tab 5mg(Taltirelin Hydrate) in Patients With Ataxia Induced by Spinocerebellar DegenerationSpinocerebellar DegenerationDrug: C-Trelin OD Tab(5mg Taltirelin Hydrate);Drug: PlaceboChem Tech Research IncorporationRecruiting20 YearsN/AAll166Phase 4Korea, Republic of
2NCT02889302November 15, 201618 December 2018An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)An Additional Phase III Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)Spinocerebellar DegenerationDrug: Placebo;Drug: KPS-0373Kissei Pharmaceutical Co., Ltd.Not recruiting20 YearsN/AAll203Phase 3Japan
3JPRN-UMIN0000107232014/01/1721 May 2019Therapeutic Effects of Neurofeedback in Neurological DisordersTherapeutic Effects of Neurofeedback in Neurological Disorders - Therapeutic Effects of Neurofeedback in Neurological DisordersParkinsonism Spinocerebellar Degeneration Stroke(with motor deficit[upper limb impairment/ gait and balance disorder]/ with speech dsyfunction)Subjects are provideed feedback of cortical activity during task, and they are asked to try enhance their cortical activation during task.
After baseline clinical assessment, participant were provided Neurofeedback-based training three sessions per week for two weeks. In the Neurofeedback-basesd training, they were asked to imagine gait and balance related motorimagery, and the cortical activation signal were provided as feedback. All participants were provided usual rehabilitative intervention up to 180 min per day for more than 5 times per week, until two weeks passes after neurofeedback intervention were finished.
In patients participated study for gait disturbance as primary outcome, daily therapy should include at least 60 minutes of physical therapy. In patients participated study for upper limb paresis as outcome measures, daily therapy should include at least 60 minutes of occupational therapy. In patients participated study for aphasia as primary outcome measures, daily therapy should include at least 60 minutes of speech therapy.

Subjects are asked to try enhance their cortical activation during task, but they are provideed cortical activity from other subject. (Control)
After baseline clinical assessment, participant were provided Neurofeedback-based training three sessions per week for two weeks. In the Neurofeedback-basesd training, they were asked to imagine gait and balance related motorimagery, and the cortical activation signal were provided as feedback. All participants were provided usual rehabilitative intervention (including at least 60 minutes of physical and/or occupational therapy) up to 180 min per day for more than 5 times per week, until two weeks passes after neurofeedback intervention were finished.
In patients participated study for gait disturbance as primary outcome, daily therapy should include at least 60 minutes of physical therapy. In patients participated study for upper limb paresis as outcome measures, daily therapy shoul
Dept. of Neurology, Osaka University Graduate School of MedicineMorinomiya Hospital Kawasaki Medical SchoolNot Recruiting20years-old85years-oldMale and Female180Phase 2,3Japan
4NCT01970098October 9, 201318 December 2018A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)A Phase III Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)Spinocerebellar DegenerationDrug: KPS-0373, High dose;Drug: KPS-0373, Low dose;Drug: PlaceboKissei Pharmaceutical Co., Ltd.Not recruiting20 YearsN/AAll374Phase 3Japan
5NCT01970111October 201325 April 2016An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)Spinocerebellar DegenerationDrug: KPS-0373, High dose;Drug: KPS-0373, Low doseKissei Pharmaceutical Co., Ltd.Not recruiting20 YearsN/ABothPhase 3Japan
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT01970124October 201325 April 2016A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)Spinocerebellar DegenerationDrug: KPS-0373, High dose;Drug: KPS-0373, Low doseKissei Pharmaceutical Co., Ltd.Not recruiting20 YearsN/ABothPhase 3Japan
7NCT01970137October 201325 April 2016A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)Spinocerebellar DegenerationDrug: KPS-0373, High dose;Drug: KPS-0373, Low doseKissei Pharmaceutical Co., Ltd.Not recruiting20 YearsN/ABothPhase 3Japan
8JPRN-UMIN0000115602013/08/302 April 2019Trial of varenicline (Champix) for the treatment of spinocerebellar degenerationspinocerebellar degeneration (SCD)[High-dose Group]
Oral administration of varenicline

1-7 days 0.5 mg/day
8-14 days 1.0mg/day
15-21 days 1.5mg/day
22-56 days 2.0 mg/day
57-63 days 1.0 mg/day
64-70 days 0.5 mg/day
71-84 days Wash-out period
85-154 days 0.5 mg/day
[Low-dose Group]
Oral administration of varenicline

1-70 days 0.5 mg/day
71-84 days Wash-out period
85-91 days 0.5 mg/day
92-98 days 1.0mg/day
99-105 days 1.5mg/day
106-140 days 2.0 mg/day
141-147 days 1.0 mg/day
148-154 days 0.5 mg/day
Niigata UniversityRecruiting20years-oldNot applicableMale and Female40Phase 1,2Japan
9JPRN-UMIN0000111112013/07/162 April 2019Spinal blood flow and metabolism in neurological diseasesmotor neuron disease including ALS, multiple sclerosis, stroke, Parkinson disease, spinocerebellar degeneration, multiple system atrophyPET scan study with 11C-flumazenil
PET scan study with 18F- FDG
PET scan study with 15O-H2O
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical SciencesRecruiting20years-oldNot applicableMale and Female70Not applicableJapan
10NCT01384435June 201119 February 2015A Phase II Double Blind Comparative Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)A Randomized, Double Blind, Placebo-controlled Phase II Study of KPS-0373 in Patients With SCDSCDDrug: KPS-0373;Drug: PlaceboKissei Pharmaceutical Co., Ltd.Not recruiting20 YearsN/ABoth200Phase 2Japan
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT01004016October 200919 February 2015A Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)A Double-blind, Placebo-controlled, Crossover Study, Followed by Open-label Study of KPS-0373 in Patients With SCDSpinocerebellar DegenerationDrug: KPS-0373;Drug: PlaceboKissei Pharmaceutical Co., Ltd.Not recruiting20 YearsN/ABoth20Phase 2Japan
12NCT00863538November 200419 February 2015Phase II Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)An Open-label, Phase II Study of KPS-0373 in Patients With SCDSpinocerebellar DegenerationDrug: KPS-0373Kissei Pharmaceutical Co., Ltd.Not recruiting20 YearsN/ABoth40Phase 2Japan
13NCT00034242April 200219 February 2015High-Dose Intravenous Immunoglobulin to Treat Cerebellar DegenerationThe Efficacy of High-Dose Intravenous Immunoglobulin Therapy In Patients With Cerebellar Degeneration: A Double Blind, Placebo Controlled TrialSpinocerebellar DegenerationsDrug: high-dose intravenous immunoglobulin (IVIG)National Institute of Neurological Disorders and Stroke (NINDS)Not recruitingN/AN/ABoth20Phase 2United States
14JPRN-JapicCTI-05003123 April 2019Intrathecal Baclofen therapy with the implanted pump system for Spastic Palsy (Post-marketing clinical trial extended phase 3 after NDA approval)Intrathecal Baclofen therapy with the implanted pump system for Spastic Palsy (Post-marketing clinical trial extended phase 3 after NDA approval)[Spinal cord Origin] Spinal cord Injury, Multiple sclerosis, Spinocerebellar degeneration, Circulatory disorder of the spinal, Ossification of the posterior longitudinal ligament [Cerebral Origin] Cerebral palsy, Traumatic head injuryIntervention name : Baclofen
Dosage And administration of the intervention : Intertheacal injection
DAIICHI SANKYO COMPANY, LIMITEDBOTHPhase 4

先頭へ